Current Status of Immunosuppressive Therapy in Renal Transplantation

For individuals with end-stage renal disease, kidney transplantation remains the leading treatment choice, offering significant benefits in terms of survival and life satisfaction. However, long-term graft survival is challenged by acute and chronic rejection, drug toxicity, infections, and malignancies. Traditional immunosuppressive regimens, including calcineurin inhibitors, antimetabolites, corticosteroids, and mTOR inhibitors, have significantly improved short-term outcomes but are associated with serious side effects. Recent advancements in immunosuppressive therapy focus on novel strategies such as co-stimulation blockers, protein kinase C inhibitors, JAK-STAT inhibitors, complement inhibitors, and regulatory T-cell therapies. Additionally, precision medicine approaches, including biomarker-guided immunosuppression and pharmacogenomics, are being explored to optimize therapy while minimizing adverse effects. This review outlines current immunosuppressive approaches and emerging therapies, highlighting how these drugs modulate immune system activity in renal transplant recipients. It also discusses the complications linked to immunosuppressive treatment, with an emphasis on enhancing long-term graft survival and patient outcomes.